Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-02-20 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司全资子公司昆药集团医药商业有限公司为玉溪昆药劲益医药有限公司申请600万元银行综合授信额度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a guarantee provided by a wholly-owned subsidiary of the company for a bank credit facility. It details the guarantee amount, the parties involved, financial data of the guaranteed company, and board opinions on the guarantee. There is no indication that this is a financial report, audit, or earnings release. The content focuses on a financing-related guarantee and credit facility, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is Capital/Financing Update (CAP).
2020-02-20 Chinese
关于控股股东华立医药集团有限公司向公司提供借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party transaction where the controlling shareholder provides a loan to the company. It details the loan amount, interest rate, purpose, terms, and the approval process by the board. There are no financial statements or comprehensive financial data presented, and the document is relatively short (3656 characters). It is a formal disclosure of a financing-related transaction but not a full financial report or earnings release. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising or financing activities.
2020-02-20 Chinese
九届十四次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed by the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, voting results, and references a related announcement (2020-018) about a loan from the controlling shareholder. The document is short (515 characters) and serves as an official notice of a board decision rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the board resolution. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2020-02-20 Chinese
2020年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2020 First Extraordinary General Meeting (EGM) Meeting Materials" of KPC Pharmaceuticals, Inc. It contains detailed information about the meeting agenda, voting procedures, and a specific proposal regarding a related-party loan transaction. The content includes meeting notices, agenda, voting methods, and detailed explanations of the proposal to be voted on. This matches the description of materials shared during a shareholders' meeting, specifically an Extraordinary General Meeting, which falls under the category of AGM Information (AGM-R). The document is not a report itself but the meeting materials for the shareholders' meeting. Therefore, the correct classification is AGM Information (AGM-R).
2020-02-11 Chinese
九届二十一次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 21st meeting of the 9th board, including approval of a loan proposal and the calling of an extraordinary general meeting. The document is short (715 characters) and serves as an official announcement of board decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG).
2020-02-05 Chinese
关于召开2020年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2020 first extraordinary general meeting of shareholders (临时股东大会) for Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 2783 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-02-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.